|
| Friday, October 18, 2024 |
|
|
Everest Medicines' Stock Price Rises by 20% as Profit Potential Drives Valuation Recovery |
| Everest Medicines (1952.HK) closed today with a 20.46% increase, hitting a high of HKD 28.6. The company's stock price has been steadily rising since the release of its interim results, with today's trading volume reaching HKD 291 million. Market updates show that BOCOM International released a report assigning an 'outperform' rating to the Chinese pharmaceutical sector, with Everest Medicines being one of the key recommended stocks. more info >> |
|
|
云顶新耀股价升两成 盈利潜力助力估值修复 |
| 云顶新耀(1952.HK)今日收盘升20.46%，最高触及28.6港元，公司自公布中期业绩开始股价一路向好，今日成交额达2.91亿元。消息层面看到，交银国际发表报告称，予内地医药行业“领先”评级，其中重点推荐了云顶新耀等一众股票。 more info >> |
|
|
雲頂新耀股價升兩成 盈利潛力助力估值修復 |
| 雲頂新耀(1952.HK)今日收盤升20.46%，最高觸及28.6港元，公司自公佈中期業績開始股價一路向好，今日成交額達2.91億元。消息層面看到，交銀國際發表報告稱，予內地醫藥行業「領先」評級，其中重點推薦了雲頂新耀等一眾股票。 more info >> |
|
| Thursday, October 3, 2024 |
|
|
云顶新耀耐赋康®入选《2024版KDIGO指南草案》，中期业绩强劲增长，展现行业领军地位 |
| 近日，云顶新耀再度传来利好消息，其核心产品耐赋康®（布地奈德肠溶胶囊，NEFECON®）作为唯一的对因治疗药物，被纳入《2024版KDIGO IgA肾病和IgA血管炎临床管理实践指南（公开审查草案）》(以下简称"新版指南（草案）")，推荐有疾病进展风险的IgA肾病患者进行9个月的耐赋康®治疗（2B）。 more info >> |
|
| Wednesday, October 2, 2024 |
|
|
NEFECON Included in 2024 KDIGO Clinical Practice Guidelines |
| Recently, Everest Medicines has announced another positive development. The company's lead product, NEFECON, as the only in-disease IgA nephropathy (IgAN) treatment, has been included in the "KDIGO 2024 Clinical Practice Guideline for the Management Of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)" (hereinafter referred to as the "New Guidelines (Draft)"), recommending treatment with a 9-month course of NEFECON for patients who are at risk of progressive kidney function loss with IgAN (2B). more info >> |
|
|
云顶新耀耐赋康入选《2024版KDIGO指南草案》 中期业绩强劲增长 展现行业领军地位 |
| 近日，云顶新耀再度传来利好消息，其核心产品耐赋康（布地奈德肠溶胶囊，NEFECON）作为唯一的对因治疗药物，被纳入《2024版KDIGO IgA肾病和IgA血管炎临床管理实践指南（公开审查草案）》(以下简称“新版指南（草案）”)，推荐有疾病进展风险的IgA肾病患者进行9个月的耐赋康治疗（2B）。 more info >> |
|
|
雲頂新耀耐賦康入選《2024版KDIGO指南草案》 中期業績強勁增長 展現行業領軍地位 |
| 近日，雲頂新耀再度傳來利好消息，其核心產品耐賦康（布地奈德腸溶膠囊，NEFECON）作為唯一的對因治療藥物，被納入《2024版KDIGO IgA腎病和IgA血管炎臨床管理實踐指南（公開審查草案）》(以下簡稱「新版指南（草案）」)，推薦有疾病進展風險的IgA腎病患者進行9個月的耐賦康治療（2B）。 more info >> |
|
| Thursday, August 29, 2024 |
|
|
云顶新耀发布2024上半年业绩：收入大幅增长158%，首次实现商业化盈利 |
| 云顶新耀发布2024年度中期业绩报告。报告显示，2024年上半年公司总收入达到人民币3.02亿元，较2023年下半年大幅增长158%。运营费用占收入的比例大幅减少249%，反映出运营效率的显著提升。非国际财务准则亏损缩减了35%，剔除非现金项目后，毛利率达到83%，实现公司历史上的首次商业化层面盈利。同时公司现金余额仍十分充足，达19.3亿元，为未来的业务发展和持续增长提供了坚实保障。 more info >> |
|
|
雲頂新耀發佈2024上半年業績：收入大幅增長158%，首次實現商業化盈利 |
| 雲頂新耀發佈2024年度中期業績報告。報告顯示，2024年上半年公司總收入達到人民幣3.02億元，較2023年下半年大幅增長158%。運營費用占收入的比例大幅減少249%，反映出運營效率的顯著提升。非國際財務準則虧損縮減了35%，剔除非現金項目後，毛利率達到83%，實現公司歷史上的首次商業化層面盈利。同時公司現金餘額仍十分充足，達19.3億元，為未來的業務發展和持續增長提供了堅實保障。 more info >> |
|
| Thursday, August 22, 2024 |
|
|
Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the launch of an Investigator-Initiated Clinical Trial (IIT) for a personalized mRNA cancer vaccine, EVM16, under the study EVM16CX01, at the Peking University Cancer Hospital and Fudan University's Cancer Hospital. more info >> |
|
|
|
|
